AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 33033062 — intervention group
Group type: EXPERIMENTAL
Intervention: Active acupressure wristbands
Number of subjects: 57
Study 33033062 — intervention group
Group type: COMPARATOR
Intervention: Placebo acupressure wristbands
Number of subjects: 57
Study 34937085 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate loading with temporary restorations
Number of subjects: 24
Study 34937085 — intervention group
Group type: COMPARATOR
Intervention: Early loading without temporary restorations
Number of subjects: 24
Study 34990208 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab 200 mg once every 3 weeks for 35 cycles
Number of subjects: 90
Study 33119048 — intervention group
Group type: EXPERIMENTAL
Intervention: Toca 511/FC
Number of subjects: 403
Study 33119048 — intervention group
Group type: COMPARATOR
Intervention: SOC
Number of subjects: 403
Study 35835476 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile app for community health and nutrition workers (CHNWs)
Number of subjects: 9033
Study 33819508 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual Immunotherapy (SLIT)
Number of subjects: 84
Study 33819508 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous Immunotherapy (SCIT)
Number of subjects: 84
Study 33819508 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous Immunotherapy (SCIT) and Sublingual Immunotherapy (SLIT)
Number of subjects: 84
Study 32590137 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritonavir-boosted lopinavir (LPV/r)
Number of subjects: 212
Study 32590137 — intervention group
Group type: COMPARATOR
Intervention: Efavirenz
Number of subjects: 212
Study 35226081 — intervention group
Group type: EXPERIMENTAL
Intervention: S-1 plus oxaliplatin (SOX) - 130 mg/m2 oxaliplatin on day 1 and 80 to 120 mg/d S-1 orally daily for 2 weeks, 6 cycles (2-4 preoperative and 2-4 postoperative)
Number of subjects: 583
Study 35226081 — intervention group
Group type: COMPARATOR
Intervention: Fluorouracil, leucovorin, and oxaliplatin (FOLFOX) - 130 mg/m2 oxaliplatin, 400 mg/m2 fluorouracil, 400 mg/m2 leucovorin, and 2400 mg/m2 fluorouracil as 46-hour infusion on day 1, 6 cycles (2-4 preoperative and 2-4 postoperative)
Number of subjects: 583
Study 34048876 — intervention group
Group type: EXPERIMENTAL
Intervention: lopinavir/ritonavir
Number of subjects: 583
Study 34048876 — intervention group
Group type: EXPERIMENTAL
Intervention: lopinavir/ritonavir–IFN–β‐1a
Number of subjects: 583
Study 34048876 — intervention group
Group type: EXPERIMENTAL
Intervention: hydroxychloroquine
Number of subjects: 583
Study 34048876 — intervention group
Group type: COMPARATOR
Intervention: control
Number of subjects: 583
Study 33183666 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic intervention (two daily capsules containing Lactobacillus rhamnosus, Saccharomyces cerevisiae, and Bifidobacterium animalis)
Number of subjects: 1
Study 33183666 — intervention group
Group type: COMPARATOR
Intervention: Placebo (identical capsule without probiotics)
Number of subjects: 1
Study 34903380 — intervention group
Group type: EXPERIMENTAL
Intervention: Cis‐RT + CP
Number of subjects: 0
Study 34903380 — intervention group
Group type: COMPARATOR
Intervention: CP
Number of subjects: 0
Study 34324661 — intervention group
Group type: EXPERIMENTAL
Intervention: PD-L1 positive expression (54% of cases)
Number of subjects: 50
Study 34324661 — intervention group
Group type: COMPARATOR
Intervention: PD-L1 negative expression (46% of cases)
Number of subjects: 50
Study 32110986 — intervention group
Group type: EXPERIMENTAL
Intervention: 140 mg of Zynamite® combined with 140 mg of quercetin
Number of subjects: 57
Study 32110986 — intervention group
Group type: COMPARATOR
Intervention: Placebo (728 mg of maltodextrin)
Number of subjects: 57
Study 36395782 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard of care plus Xpert MTB/RIF Ultra on nasopharyngeal aspirate and stool samples
Number of subjects: 2570
Study 36395782 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (control group)
Number of subjects: 2570
Study 36395782 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard of care plus Xpert MTB/RIF Ultra
Number of subjects: 2570
Study 33423321 — intervention group
Group type: EXPERIMENTAL
Intervention: See‐see partridges (Ammoperdix griseogularis)
Number of subjects: 20
Study 33423321 — intervention group
Group type: COMPARATOR
Intervention: Pheasants (Phasianus colchicus)
Number of subjects: 20
Study 35724357 — intervention group
Group type: EXPERIMENTAL
Intervention: octreotide long-acting release (octLAR)
Number of subjects: 51
Study 35724357 — intervention group
Group type: COMPARATOR
Intervention: lanreotide
Number of subjects: 51
Study 33285745 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Maimendong Decoction (MMD) plus Pirfenidone capsule
Number of subjects: 60
Study 33285745 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus Pirfenidone capsule
Number of subjects: 60
Study 35267915 — intervention group
Group type: EXPERIMENTAL
Intervention: Liquid diet (LD) group
Number of subjects: 127
Study 35267915 — intervention group
Group type: COMPARATOR
Intervention: DPP group
Number of subjects: 127
Study 33061822 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucagon-like peptide-1 receptor agonist (GLP-1RA)
Number of subjects: 0
Study 33061822 — intervention group
Group type: COMPARATOR
Intervention: Lipid infusion
Number of subjects: 0
Study 33061822 — intervention group
Group type: COMPARATOR
Intervention: Healthy women (control group)
Number of subjects: 0
Study 33061822 — intervention group
Group type: EXPERIMENTAL
Intervention: PCOS women
Number of subjects: 0
Study 35200147 — intervention group
Group type: EXPERIMENTAL
Intervention: BitHabit app with face-to-face group coaching
Number of subjects: 1926
Study 35200147 — intervention group
Group type: EXPERIMENTAL
Intervention: BitHabit app alone
Number of subjects: 1926
Study 35200147 — intervention group
Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 1926
Study 34380810 — intervention group
Group type: EXPERIMENTAL
Intervention: BioHPP PEEK inlays
Number of subjects: 40
Study 34380810 — intervention group
Group type: COMPARATOR
Intervention: Zirconia inlays
Number of subjects: 40
Study 32718426 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-assisted instrument guidance (CAIG)
Number of subjects: 26
Study 32718426 — intervention group
Group type: COMPARATOR
Intervention: Standalone ultrasonography (US)
Number of subjects: 26
Study 35397798 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled budesonide at a dose of 800 μg twice a day plus usual care
Number of subjects: 146
Study 35397798 — intervention group
Group type: COMPARATOR
Intervention: Usual care (as needed antipyretics)
Number of subjects: 146
Study 34644233 — intervention group
Group type: EXPERIMENTAL
Intervention: Pasteurized 100% watermelon juice (360 mL servings, 2 servings per day for 4 weeks)
Number of subjects: 16
Study 34644233 — intervention group
Group type: COMPARATOR
Intervention: Placebo beverage (360 mL servings, 2 servings per day for 4 weeks)
Number of subjects: 16
Study 32691228 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular quadratus lumborum block (QLBi) with 0.4 mL/kg of 0.25% ropivacaine
Number of subjects: 36
Study 32691228 — intervention group
Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 36
Study 33475876 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced external counterpulsation (EECP) therapy
Number of subjects: 168
Study 33475876 — intervention group
Group type: COMPARATOR
Intervention: Standard medical treatment
Number of subjects: 168
Study 33938582 — intervention group
Group type: EXPERIMENTAL
Intervention: Parenting Support Program (PSP)
Number of subjects: 29
Study 33938582 — intervention group
Group type: COMPARATOR
Intervention: Wait-list (WL) group
Number of subjects: 29
Study 35107023 — intervention group
Group type: EXPERIMENTAL
Intervention: TLR4 neutralizing antibodies
Number of subjects: 13
Study 35107023 — intervention group
Group type: COMPARATOR
Intervention: IgG (control)
Number of subjects: 13
Study 32958702 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenalidomide concurrent with PCV13 vaccine (arm A)
Number of subjects: 49
Study 32958702 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenalidomide sequential to PCV13 vaccine (arm B)
Number of subjects: 49
Study 32958702 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenalidomide (both arms)
Number of subjects: 49
Study 32958702 — intervention group
Group type: COMPARATOR
Intervention: Lenalidomide
Number of subjects: 49
Study 35989210 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile phone intervention for tracking pregnant women
Number of subjects: 248
Study 35989210 — intervention group
Group type: COMPARATOR
Intervention: Control group (no mobile phone intervention)
Number of subjects: 248
Study 33818131 — intervention group
Group type: EXPERIMENTAL
Intervention: Halyard Fluidshield® N95
Number of subjects: 96
Study 33818131 — intervention group
Group type: COMPARATOR
Intervention: BSN Medical ProShield® N-95
Number of subjects: 96
Study 33818131 — intervention group
Group type: EXPERIMENTAL
Intervention: User seal check for both masks
Number of subjects: 96
Study 33818131 — intervention group
Group type: EXPERIMENTAL
Intervention: Both masks
Number of subjects: 96
Study 32323163 — intervention group
Group type: EXPERIMENTAL
Intervention: Task 2 was IM-compatible
Number of subjects: 0
Study 32323163 — intervention group
Group type: COMPARATOR
Intervention: Single-task trials (baseline)
Number of subjects: 0
Study 36345090 — intervention group
Group type: EXPERIMENTAL
Intervention: smTAP
Number of subjects: 65
Study 36345090 — intervention group
Group type: COMPARATOR
Intervention: EMST
Number of subjects: 65
Study 33881673 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT)
Number of subjects: 24
Study 33881673 — intervention group
Group type: EXPERIMENTAL
Intervention: Er,Cr:YSGG laser (0.25 W and 0.5 W)
Number of subjects: 24
Study 33881673 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoride varnish
Number of subjects: 24
Study 33881673 — intervention group
Group type: COMPARATOR
Intervention: Placebo laser
Number of subjects: 24
Study 32960073 — intervention group
Group type: EXPERIMENTAL
Intervention: Sexual Health Counseling based on REDI Model
Number of subjects: 104
Study 32960073 — intervention group
Group type: COMPARATOR
Intervention: Control Group (no intervention)
Number of subjects: 104
Study 35384387 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronized progesterone (100 mg)
Number of subjects: 24
Study 35384387 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 32323014 — intervention group
Group type: EXPERIMENTAL
Intervention: MVLSD
Number of subjects: 60
Study 32323014 — intervention group
Group type: COMPARATOR
Intervention: CLSD
Number of subjects: 60
Study 33390353 — intervention group
Group type: EXPERIMENTAL
Intervention: Water Exchange (WE) method
Number of subjects: 450
Study 33390353 — intervention group
Group type: COMPARATOR
Intervention: Air-Insufflated (AI) method
Number of subjects: 450
Study 32583297 — intervention group
Group type: EXPERIMENTAL
Intervention: UDCA 600 mg/day for 6 months
Number of subjects: 190
Study 32583297 — intervention group
Group type: COMPARATOR
Intervention: Control group (no UDCA)
Number of subjects: 190
Study 32583297 — intervention group
Group type: EXPERIMENTAL
Intervention: UDCA group
Number of subjects: 190
Study 32583297 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 190
Study 32583297 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 190
Study 35241243 — intervention group
Group type: EXPERIMENTAL
Intervention: ICD implantation
Number of subjects: 1116
Study 35241243 — intervention group
Group type: COMPARATOR
Intervention: Usual clinical care
Number of subjects: 1116
Study 34935138 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdiagnostic behavior therapy (TBT)
Number of subjects: 40
Study 34935138 — intervention group
Group type: COMPARATOR
Intervention: Behavioral activation treatment for depression (BATD)
Number of subjects: 40
Study 32147296 — intervention group
Group type: EXPERIMENTAL
Intervention: SMS reminders only
Number of subjects: 1594
Study 32147296 — intervention group
Group type: EXPERIMENTAL
Intervention: SMS reminder and personalised calendar
Number of subjects: 1594
Study 32147296 — intervention group
Group type: COMPARATOR
Intervention: Personalised calendar
Number of subjects: 1594
Study 32147296 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control)
Number of subjects: 1594
Study 32147296 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control) after 'No Jab, No Pay' policy
Number of subjects: 1594
Study 35297288 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized within-patient controlled trial design
Number of subjects: 1
Study 35297288 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental condition (non-active bone grafts)
Number of subjects: 1
Study 35297288 — intervention group
Group type: COMPARATOR
Intervention: Control condition (standard treatment)
Number of subjects: 1
Study 32635288 — intervention group
Group type: EXPERIMENTAL
Intervention: Proprioceptive training with the use of virtual reality (VR)
Number of subjects: 21
Study 32635288 — intervention group
Group type: COMPARATOR
Intervention: Control group without training
Number of subjects: 21
Study 36209764 — intervention group
Group type: EXPERIMENTAL
Intervention: Iberdomide plus dexamethasone (0.3-1.6 mg on days 1-21 of each 28-day cycle; dexamethasone 40 mg once per week, 20 mg if age >75 years)
Number of subjects: 197
Study 36209764 — intervention group
Group type: EXPERIMENTAL
Intervention: Iberdomide plus dexamethasone
Number of subjects: 197
Study 34268887 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised exercise program
Number of subjects: 37
Study 34268887 — intervention group
Group type: COMPARATOR
Intervention: Home exercise program
Number of subjects: 37
Study 32614825 — intervention group
Group type: EXPERIMENTAL
Intervention: gSOS (polygenic risk score for heel quantitative ultrasound speed of sound)
Number of subjects: 10522
Study 32614825 — intervention group
Group type: COMPARATOR
Intervention: Guideline recommendations without genetic prescreening
Number of subjects: 10522
Study 33977560 — intervention group
Group type: EXPERIMENTAL
Intervention: Varenicline 0.5 mg po b.i.d.
Number of subjects: 33
Study 33977560 — intervention group
Group type: EXPERIMENTAL
Intervention: Varenicline doses (0.25 mg per day, 0.25 mg b.i.d., 0.5 mg b.i.d., and 1.0 mg b.i.d.)
Number of subjects: 33
Study 33977560 — intervention group
Group type: EXPERIMENTAL
Intervention: Varenicline
Number of subjects: 33
Study 33167780 — intervention group
Group type: EXPERIMENTAL
Intervention: umeclidinium/vilanterol
Number of subjects: 2425
Study 33167780 — intervention group
Group type: COMPARATOR
Intervention: umeclidinium
Number of subjects: 2425
Study 33167780 — intervention group
Group type: COMPARATOR
Intervention: salmeterol
Number of subjects: 2425
Study 36206950 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial invasive management with angiography, revascularization when feasible, and guideline-directed medical therapy (GDMT)
Number of subjects: 5956
Study 36206950 — intervention group
Group type: COMPARATOR
Intervention: Initial conservative management with GDMT alone and angiography reserved for failure of medical therapy
Number of subjects: 5956
Study 36206950 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term follow-up of surviving participants from ISCHEMIA and ISCHEMIA-CKD trials
Number of subjects: 5956
Study 33797063 — intervention group
Group type: EXPERIMENTAL
Intervention: Bafiertam™ (MMF) 190 mg as 2 × 95 mg delayed-release capsules
Number of subjects: 50
Study 33797063 — intervention group
Group type: COMPARATOR
Intervention: Tecfidera® (DMF) 240 mg as 1 × 240 mg delayed-release capsule
Number of subjects: 50
Study 33051441 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (40 mg)
Number of subjects: 127
Study 33051441 — intervention group
Group type: COMPARATOR
Intervention: Placebo (vitamin C)
Number of subjects: 127
Study 34350569 — intervention group
Group type: EXPERIMENTAL
Intervention: Potassium (K) at 11.6 mmol L‐1
Number of subjects: 0
Study 34350569 — intervention group
Group type: COMPARATOR
Intervention: Cadmium (Cd) at 1.5 mmol L‐1
Number of subjects: 0
Study 33785077 — intervention group
Group type: EXPERIMENTAL
Intervention: Exergaming (stepping exergame program, 8 weeks, 3 times weekly, 15 min per session)
Number of subjects: 45
Study 33785077 — intervention group
Group type: COMPARATOR
Intervention: Control (watching preferred music videos)
Number of subjects: 45
Study 32315295 — intervention group
Group type: EXPERIMENTAL
Intervention: Letrozole monotherapy in real-world cohort
Number of subjects: 107
Study 32315295 — intervention group
Group type: COMPARATOR
Intervention: Letrozole 2.5 mg/d in PALOMA-2 trial cohort
Number of subjects: 107
Study 35266375 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg oral gabapentin
Number of subjects: 72
Study 35266375 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study 35279906 — intervention group
Group type: EXPERIMENTAL
Intervention: ET CO2 = 40 mmHg
Number of subjects: 64
Study 35279906 — intervention group
Group type: EXPERIMENTAL
Intervention: ET CO2 = 35 mmHg
Number of subjects: 64
Study 35279906 — intervention group
Group type: EXPERIMENTAL
Intervention: ET CO2 = 45 mmHg
Number of subjects: 64
Study 35279906 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation analysis
Number of subjects: 64
Study 35696263 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention (8-week diet-induced rapid weight loss followed by 148-week lifestyle-based weight maintenance)
Number of subjects: 1510
Study 35696263 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention
Number of subjects: 1510
Study 33879597 — intervention group
Group type: EXPERIMENTAL
Intervention: SMA neurofeedback facilitation using fNIRS (6 sessions)
Number of subjects: 54
Study 33879597 — intervention group
Group type: COMPARATOR
Intervention: Sham (placebo) intervention
Number of subjects: 54
Study 33112722 — intervention group
Group type: EXPERIMENTAL
Intervention: FW-squat
Number of subjects: 15
Study 33112722 — intervention group
Group type: EXPERIMENTAL
Intervention: FW-deadlift
Number of subjects: 15
Study 33112722 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 15
Study 33999472 — intervention group
Group type: EXPERIMENTAL
Intervention: Tip-modified curve (group T)
Number of subjects: 120
Study 33999472 — intervention group
Group type: COMPARATOR
Intervention: Standard curve (group S)
Number of subjects: 120
Study 32502940 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy (NaCT)
Number of subjects: 217
Study 32502940 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant endocrine therapy (NET)
Number of subjects: 217
Study 35834251 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin plus fluocinolone
Number of subjects: 493
Study 35834251 — intervention group
Group type: COMPARATOR
Intervention: Ciprofloxacin
Number of subjects: 493
Study 35834251 — intervention group
Group type: COMPARATOR
Intervention: Fluocinolone
Number of subjects: 493
Study 34702296 — intervention group
Group type: EXPERIMENTAL
Intervention: New predictive equation A based on anthropometric parameters
Number of subjects: 126
Study 34702296 — intervention group
Group type: EXPERIMENTAL
Intervention: New predictive equation B based on BIA-derived raw variables
Number of subjects: 126
Study 34702296 — intervention group
Group type: COMPARATOR
Intervention: Existing equations from literature
Number of subjects: 126
Study 34702296 — intervention group
Group type: EXPERIMENTAL
Intervention: Selected equations (6 out of 8)
Number of subjects: 126
Study 32935171 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity resistance and impact training (HiRIT)
Number of subjects: 93
Study 32935171 — intervention group
Group type: EXPERIMENTAL
Intervention: Machine-based isometric axial compression (IAC)
Number of subjects: 93
Study 32935171 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 93
Study 32598657 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning (RIPC)
Number of subjects: 173
Study 32598657 — intervention group
Group type: COMPARATOR
Intervention: Standard primary PCI without RIPC
Number of subjects: 173
Study 35435497 — intervention group
Group type: EXPERIMENTAL
Intervention: [18F]FDG‐PET/CT
Number of subjects: 132
Study 35435497 — intervention group
Group type: COMPARATOR
Intervention: Diagnostic surgery
Number of subjects: 132
Study 34016545 — intervention group
Group type: EXPERIMENTAL
Intervention: Experienced Readers (ER)
Number of subjects: 32
Study 34016545 — intervention group
Group type: COMPARATOR
Intervention: Novice Readers (NR)
Number of subjects: 32
Study 32589978 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyper-CVAD regimen plus ofatumumab
Number of subjects: 69
Study 35536764 — intervention group
Group type: EXPERIMENTAL
Intervention: Febuxostat (40 or 80 mg, based on sUA at Week 2)
Number of subjects: 6190
Study 35536764 — intervention group
Group type: COMPARATOR
Intervention: Allopurinol (dose titrated in 100 mg increments from 200-400 mg or 300-600 mg, based on kidney function)
Number of subjects: 6190
Study 35536764 — intervention group
Group type: EXPERIMENTAL
Intervention: Febuxostat
Number of subjects: 6190
Study 35536764 — intervention group
Group type: COMPARATOR
Intervention: Allopurinol
Number of subjects: 6190
Study 35536764 — intervention group
Group type: EXPERIMENTAL
Intervention: Febuxostat and Allopurinol
Number of subjects: 6190
Study 34174917 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation support program for intervention sites including face-to-face events and on-demand components over 12 months.
Number of subjects: 20
Study 34174917 — intervention group
Group type: COMPARATOR
Intervention: Control sites with no implementation support.
Number of subjects: 20
Study 32414381 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy Lifestyles (HL) intervention
Number of subjects: 553
Study 32414381 — intervention group
Group type: COMPARATOR
Intervention: Healthy Finances (HF) control
Number of subjects: 553
Study 32105001 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional phototherapy (Group I)
Number of subjects: 40
Study 32105001 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive phototherapy (Group II)
Number of subjects: 40
Study 34622721 — intervention group
Group type: EXPERIMENTAL
Intervention: Propolis (250 mg/two times per day for three months)
Number of subjects: 60
Study 34622721 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 33860579 — intervention group
Group type: EXPERIMENTAL
Intervention: Taxane/platinum therapy (paclitaxel + carboplatin)
Number of subjects: 165
Study 33860579 — intervention group
Group type: EXPERIMENTAL
Intervention: Taxane/platinum therapy (paclitaxel + carboplatin) with additional docetaxel and nedaplatin
Number of subjects: 165